机构：[a]Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA[b]Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA[c]Department of Neurobiology and Neurology, Beijing Institute of Geriatrics, Xuanwu Hospital, Capital Medical University, Beijing, China神经内科老年医学科首都医科大学宣武医院[d]Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA[e]Biochemistry Department and Experimental Biochemistry Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia[f]Retina Foundation of the Southwest, Dallas, TX, USA[g]Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX, USA
Increased dietary consumption of docosahexaenoic acid (DHA) is associated with decreased risk for Alzheimer's disease (AD). These effects have been postulated to arise from DHA's pleiotropic effects on AD pathophysiology, including its effects on beta-amyloid (A beta) production, aggregation, and toxicity. While in vitro studies suggest that DHA may inhibit and reverse the formation of toxic A beta oligomers, it remains uncertain whether these mechanisms operate in vivo at the physiological concentrations of DHA attainable through dietary supplementation. We sought to clarify the effects of dietary DHA supplementation on A beta indices in a transgenic APP/PS1 rat model of AD. Animals maintained on a DHA-supplemented diet exhibited reductions in hippocampal A beta plaque density and modest improvements on behavioral testing relative to those maintained on a DHA-depleted diet. However, DHA supplementation also increased overall soluble A beta oligomer levels in the hippocampus. Further quantification of specific conformational populations of A beta oligomers indicated that DHA supplementation increased fibrillar (i.e. putatively less toxic) A beta oligomers and decreased prefibrillar (i.e. putatively more toxic) A beta oligomers. These results provide in vivo evidence suggesting that DHA can modulate A beta aggregation by stabilizing soluble fibrillar A beta oligomers and thus reduce the formation of both A beta plaques and prefibrillar AS oligomers. However, since fibrillar A beta oligomers still retain inherent neurotoxicity, DHA may need to be combined with other interventions that can additionally reduce fibrillar A beta oligomer levels for more effective prevention of AD in clinical settings. Published by Elsevier Inc.
基金：
the National Institute on Aging (K08AG34628)
jointly sponsored by NIA, AFAR,
the John A. Hartford Foundation,
the Atlantic Philanthropies,
the Starr Foundation and an anonymous donor and (RC1 AG035878)
第一作者机构：[a]Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA[b]Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA[*1]Neurobehavior Service (116AF), West Los Angeles VA Healthcare Center, 11301Wilshire Boulevard, Los Angeles, CA 90073, USA.
通讯作者：
通讯机构：[*1]Neurobehavior Service (116AF), West Los Angeles VA Healthcare Center, 11301Wilshire Boulevard, Los Angeles, CA 90073, USA.
推荐引用方式(GB/T 7714)：
Edmond Teng,Karen Taylor,Tina Bilousova,et al.Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and A beta pathology and modulates A beta oligomerization[J].NEUROBIOLOGY OF DISEASE.2015,82:552-560.doi:10.1016/j.nbd.2015.09.002.
APA：
Edmond Teng,Karen Taylor,Tina Bilousova,DavidWeiland,Thaidan Pham...&Gregory M. Cole.(2015).Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and A beta pathology and modulates A beta oligomerization.NEUROBIOLOGY OF DISEASE,82,
MLA：
Edmond Teng,et al."Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and A beta pathology and modulates A beta oligomerization".NEUROBIOLOGY OF DISEASE 82.(2015):552-560
